18 years. 2+ billion doses and counting.
Our pipeline of medicines aims to overcome barriers that patients face with existing treatment options and provide new paradigms for treating critical and complex conditions.1
2B+ doses consumed. 200+ patents provide strong intellectual property.
Aquestive is the worldwide leader in delivering trusted, quality medications on oral film. Every medicine is different, so Aquestive follows a drug-by-drug approach for harnessing PharmFilm® technology to achieve target product profiles and clinical improvement goals.
Aquestive Therapeutics is the undisputed leader in developing and delivering medications via film, through our proprietary PharmFilm® technology. We’ve used our expertise to create a robust, proprietary CNS and complex molecule portfolio.
Learn about the medicines we’re reinventing to improve treatment options for patients.
PharmFilm® is a versatile, high-performance drug delivery technology that can be uniquely tailored to achieve a desired product profile with optimized absorption, bioavailability, and onset of action.
See how Aquestive is changing drug delivery to deliver meaningful clinical and therapeutic advances.
Our innovations in oral drug delivery aim to improve the treatment experience for patients with epilepsy and their caregivers who struggle with difficult or invasive modes of administration, complex treatment regimens, and inconsistent dosing and drug delivery.2 Our efforts to help patients and families extend beyond the clinic.
Aquestive is a pharmaceutical company that advances and commercializes medicines to solve therapeutic problems and meaningfully improve people’s lives. We apply innovative drug delivery technology and scientific expertise to redesign important medicines. Our initial focus, supported by our current approved products and late-stage pipeline, is to improve medications and outcomes for patients with central nervous system (CNS) conditions.
Aquestive works hand-in-hand with our partners to address their toughest challenges—enhancing existing molecules and providing a development platform for new ones. We have comprehensive capabilities to advance medicines from pipeline to market. Partners can rely on our scientific and regulatory expertise, integrated development capabilities, and world-class clinical and commercial manufacturing operations. More than 2 billion commercial doses have been delivered with our PharmFilm® technology.
AQST-109 is the first and only orally delivered epinephrine product candidate in clinical development Fastest median time to maximum concentration (Tmax) in studies to date at 12 minutes Study continues to show AQST-109 is safe and well tolerated Head-to-head comparison study to EpiPen® scheduled
WARREN, N.J. , June 08, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it has closed its
WARREN, N.J. , June 07, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management team
1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76.
2. Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109–117.